当前位置: X-MOL 学术Stress › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Vasopressin and post-traumatic stress disorder
Stress ( IF 2.6 ) Pub Date : 2020-10-12 , DOI: 10.1080/10253890.2020.1826430
Eszter Sipos 1 , Bibiána Török 1, 2 , István Barna 1 , Mario Engelmann 3, 4 , Dóra Zelena 1, 5
Affiliation  

Abstract

Post-traumatic stress disorder (PTSD) is a debilitating psychiatric condition with a wide range of behavioral disturbances and serious consequences for both patient and society. One of the main reasons for unsuccessful therapies is insufficient knowledge about its underlying pathomechanism. In the search for centrally signaling molecules that might be relevant to the development of PTSD we focus here on arginine vasopressin (AVP). So far AVP has not been strongly implicated in PTSD, but different lines of evidence suggest a possible impact of its signaling in all clusters of PTSD symptomatology. More specifically, in laboratory rodents, AVP agonists affect behavior in a PTSD-like manner, while significant reduction of AVP signaling in the brain e.g. in AVP-deficient Brattleboro rats, ameliorated defined behavioral parameters that can be linked to PTSD symptoms. Different animal models of PTSD also show alterations in the AVP signaling in distinct brain areas. However, pharmacological treatment targeting central AVP receptors via systemic routes is hampered by possible side effects that are linked to the peripheral action of AVP as a hormone. Indeed, the V1a receptor, the most common receptor subtype in the brain, is implicated in vasoconstriction. Thus, systemic treatment with V1a receptor antagonists would be implicated in hypotonia. This implies that novel treatment concepts are needed to target AVP receptors not only at brain level but also in distinct brain areas, to offer alternative treatments for PTSD.



中文翻译:

加压素和创伤后应激障碍

摘要

创伤后应激障碍(PTSD)是一种使人精神衰弱的疾病,其行为紊乱范围广,对患者和社会均造成严重后果。治疗失败的主要原因之一是对其潜在的致病机理了解不足。在寻找可能与PTSD的发展有关的集中信号分子时,我们将重点放在精氨酸加压素(AVP)上。到目前为止,尚未将AVP与PTSD密切相关,但是不同的证据表明,其信号可能对PTSD症状的所有群集都有影响。更具体地说,在实验室啮齿动物中,AVP激动剂以类似PTSD的方式影响行为,而大脑中AVP信号的显着降低,例如在缺乏AVP的Brattleboro大鼠中,可以与PTSD症状相关的改善的已定义行为参数。PTSD的不同动物模型还在不同的大脑区域也显示出AVP信号的变化。然而,通过全身途径靶向中枢AVP受体的药物治疗受到可能的副作用的阻碍,所述副作用与AVP作为激素的外周作用有关。实际上,V1a受体是大脑中最常见的受体亚型,与血管收缩有关。因此,用V1a受体拮抗剂进行全身治疗将导致肌张力低下。这意味着需要新颖的治疗方法,不仅在脑水平而且在不同的脑区域靶向AVP受体,以提供PTSD的替代治疗方法。然而,通过全身途径靶向中枢AVP受体的药物治疗受到可能的副作用的阻碍,所述副作用与AVP作为激素的外周作用有关。实际上,V1a受体是大脑中最常见的受体亚型,与血管收缩有关。因此,用V1a受体拮抗剂进行全身治疗将导致肌张力低下。这意味着需要新颖的治疗方法,不仅在脑水平而且在不同的脑区域靶向AVP受体,以提供PTSD的替代治疗方法。然而,通过全身途径靶向中枢AVP受体的药物治疗受到可能的副作用的阻碍,所述副作用与AVP作为激素的外周作用有关。实际上,V1a受体是大脑中最常见的受体亚型,与血管收缩有关。因此,用V1a受体拮抗剂进行全身治疗将导致肌张力低下。这意味着需要新颖的治疗方法,不仅在脑水平而且在不同的脑区域靶向AVP受体,以提供PTSD的替代治疗方法。用V1a受体拮抗剂进行全身治疗可能会导致低渗。这意味着需要新颖的治疗方法,不仅在脑水平而且在不同的脑区域靶向AVP受体,以提供PTSD的替代治疗方法。用V1a受体拮抗剂进行全身治疗可能会导致低渗。这意味着需要新颖的治疗方法,不仅在脑水平而且在不同的脑区域靶向AVP受体,以提供PTSD的替代治疗方法。

更新日期:2020-10-12
down
wechat
bug